Meaning-Centered Psychotherapy for Psilocybin-Assisted Therapy Among Patients with Advanced Cancer and Depression: Rationale and Preliminary Evaluation of MCP-PSIL.

Psychedelic medicine (New Rochelle, N.Y.) Pub Date : 2025-07-30 eCollection Date: 2026-06-01 DOI:10.1177/28314425251363983
William E Rosa, Stephanie Napolitano, Natalie McAndrew, Betsy Jenkins, Wendy G Lichtenthal, Allison J Applebaum, William Breitbart, Manish Agrawal
{"title":"Meaning-Centered Psychotherapy for Psilocybin-Assisted Therapy Among Patients with Advanced Cancer and Depression: Rationale and Preliminary Evaluation of MCP-PSIL.","authors":"William E Rosa, Stephanie Napolitano, Natalie McAndrew, Betsy Jenkins, Wendy G Lichtenthal, Allison J Applebaum, William Breitbart, Manish Agrawal","doi":"10.1177/28314425251363983","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Psilocybin shows encouraging outcomes for patients with cancer and major depressive disorder (MDD). However, there is insufficient evidence on the use of evidence-based psychotherapeutic interventions to consistently guide and standardize psilocybin preparation, dosing, and integration. Meaning-centered psychotherapy (MCP) is a manualized, brief psychotherapeutic intervention that enhances meaning and purpose among recipients. This article substantiates the rationale for using MCP as a psychotherapeutic intervention to accompany psychedelic-assisted therapy (PAT) with psilocybin for patients with cancer and MDD.</p><p><strong>Materials and methods: </strong>We sampled seven patients with cancer and MDD who previously received PAT with psilocybin followed by group MCP in a phase 2 open-label trial, as well as six therapists who delivered the interventions. First, electronic open-ended response surveys were distributed to explore participant experiences during the phase 2 trial and elicit recommendations to adapt MCP for psilocybin. Second, the research team developed a 5-session model of MCP and psilocybin therapy (MCP-PSIL) based on survey responses. Finally, four focus groups were conducted (two with patients and two with therapists) to expand on patient experiences during the phase 2 trial and gather feedback on MCP-PSIL.</p><p><strong>Results: </strong>Seven patients (ages 53-80 years) and six therapists (mental health professional experience ranging 9-44 years) participated in both surveys and focus groups. Focus groups underscored the value of experiences related to psilocybin, the group, and MCP, as distinct elements and in conjunction. Participants shared key recommendations to enhance combined psilocybin and MCP experiences and the 5-session MCP-PSIL model. The importance of the group format was also emphasized while noting that individual MCP may be indicated in certain circumstances.</p><p><strong>Conclusion: </strong>Findings suggest that MCP is a natural therapeutic partner to guide patients throughout the PAT continuum. As MCP-PSIL is tested in the future, we anticipate MCP will leverage the PAT experience by building therapist capacity to optimize care while reducing avoidable distress for patients and maximizing their meaning-making opportunities.</p>","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"4 2","pages":"97-106"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13271188/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychedelic medicine (New Rochelle, N.Y.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/28314425251363983","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Psilocybin shows encouraging outcomes for patients with cancer and major depressive disorder (MDD). However, there is insufficient evidence on the use of evidence-based psychotherapeutic interventions to consistently guide and standardize psilocybin preparation, dosing, and integration. Meaning-centered psychotherapy (MCP) is a manualized, brief psychotherapeutic intervention that enhances meaning and purpose among recipients. This article substantiates the rationale for using MCP as a psychotherapeutic intervention to accompany psychedelic-assisted therapy (PAT) with psilocybin for patients with cancer and MDD.

Materials and methods: We sampled seven patients with cancer and MDD who previously received PAT with psilocybin followed by group MCP in a phase 2 open-label trial, as well as six therapists who delivered the interventions. First, electronic open-ended response surveys were distributed to explore participant experiences during the phase 2 trial and elicit recommendations to adapt MCP for psilocybin. Second, the research team developed a 5-session model of MCP and psilocybin therapy (MCP-PSIL) based on survey responses. Finally, four focus groups were conducted (two with patients and two with therapists) to expand on patient experiences during the phase 2 trial and gather feedback on MCP-PSIL.

Results: Seven patients (ages 53-80 years) and six therapists (mental health professional experience ranging 9-44 years) participated in both surveys and focus groups. Focus groups underscored the value of experiences related to psilocybin, the group, and MCP, as distinct elements and in conjunction. Participants shared key recommendations to enhance combined psilocybin and MCP experiences and the 5-session MCP-PSIL model. The importance of the group format was also emphasized while noting that individual MCP may be indicated in certain circumstances.

Conclusion: Findings suggest that MCP is a natural therapeutic partner to guide patients throughout the PAT continuum. As MCP-PSIL is tested in the future, we anticipate MCP will leverage the PAT experience by building therapist capacity to optimize care while reducing avoidable distress for patients and maximizing their meaning-making opportunities.

以意义为中心的心理治疗对晚期癌症和抑郁症患者的辅助治疗:MCP-PSIL的基本原理和初步评价。
裸盖菇素对癌症和重度抑郁症(MDD)患者的疗效令人鼓舞。然而,关于使用循证心理治疗干预来持续指导和规范裸盖菇素的制备、给药和整合的证据不足。以意义为中心的心理治疗(MCP)是一种手动的、简短的心理治疗干预,旨在增强接受者的意义和目的。这篇文章证实了使用MCP作为一种心理治疗干预的基本原理,以伴随迷幻辅助治疗(PAT)的裸盖菇素治疗癌症和重度抑郁症患者。材料和方法:我们抽样了7名癌症和重度抑郁症患者,他们之前在2期开放标签试验中接受了psilocybin的PAT,然后是MCP组,以及6名提供干预措施的治疗师。首先,分发电子开放式回应调查,以探索二期试验期间参与者的体验,并得出将MCP用于裸盖菇素的建议。其次,研究小组根据调查结果建立了MCP和裸盖菇素治疗的5期模型(MCP- psil)。最后,进行了四个焦点小组(两个与患者一起,两个与治疗师一起),以扩大患者在2期试验中的经验,并收集关于MCP-PSIL的反馈。结果:7名患者(53 ~ 80岁)和6名治疗师(9 ~ 44年心理健康从业经验)参与了调查和焦点小组。焦点小组强调了与裸盖菇素、组和MCP相关的经验的价值,这些经验作为不同的元素并结合在一起。与会者分享了加强裸盖菇素和MCP联合经验以及5期MCP- psil模型的关键建议。会议还强调了小组形式的重要性,同时指出在某些情况下可能会指出个别MCP。结论:研究结果表明,MCP是一种天然的治疗伙伴,可以指导患者在整个PAT连续体中进行治疗。随着MCP- psil在未来的测试,我们预计MCP将利用PAT的经验,通过建立治疗师的能力来优化护理,同时减少患者可避免的痛苦,并最大限度地提高他们的意义创造机会。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书